Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 16, 2007

Pall Opens Center of Excellence in India

  • Pall inaugurated its newest Life Sciences Centre of Excellence in Bangalore, India. The Centre will drive process optimization innovations for the global life sciences market and includes a state-of-the-art proteomics laboratory to help customers speed the drug discovery process. It also houses a validation laboratory and a training facility with specialty experts to support Indian and regional customers as they increasingly enter the stringently regulated drug export market.

    India was strategically chosen as the location for Pall’s new Centre of Excellence in Asia because of the country’s reputation in life sciences spanning biopharmaceutical research, development, and production. Additionally, India’s diverse market opportunities coupled with a large pool of qualified scientists and engineers provide an ideal climate for fueling innovation and growth.

    “The success of our customers depends on their ability to carry out all stages of drug development—research, discovery and full-scale production—efficiently and cost-effectively,” says Vinay Joban, general manager, Pall BioPharmaceuticals India. “The new Centre provides the region with a complete range of services to support their operations from upstream through downstream while also facilitating their ability to comply with increasingly rigorous global requirements.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »